A Phase 4 interventional study of Pendulum WBF-038 and Pendulum Placebo in Postmenopausal Osteopenia, Bone Loss, Age Related and Age-Related Sarcopenia, sponsored by Australian Catholic University. Completed at 1 site in Australia. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Australian Catholic University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Osteoporosis with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis · Australia.
Among the 33 studies in Osteoporosis with a site in Australia, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 32nd registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →1 of the 33 studies in Osteoporosis with a site in Australia is open now. Recruiting first, the newest first:
Australian and New Zealand Intensive Care Research Centre · Sites in Australia, New Zealand
Ages 50+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 40 Years to 65 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 188 across the 32 interventional studies, 115 across the 1 observational. Of the 31 that completed or were terminated, 16 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 33 have an industry lead sponsor. The 10 most frequent:
Australian Catholic University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Australian Catholic University has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Osteoporosis with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography [HR-pQCT]) of the distal tibia.
It is well established that bone loss occurs throughout life after the attainment of peak bone mass which is usually reached by the end of the second decade of life. During the first 5-8 years following menopause, women experience an accelerated bone loss, which is then followed by a slower phase of decline in bone mineral density (BMD). As over 40% of all women in Australia will suffer an osteoporotic (fragility) fracture in their lifetime, investigating interventions that can prevent bone loss in postmenopausal women is a critical focus. The menopausal transition is also associated with an increased risk of cardiovascular disease, diabetes, and cognitive decline. These conditions and their treatments can also affect bone health.
Previous research has indicated a potential link between the gut microbiome and bone health. Animal studies indicate that interventions affecting the gut microbiome may be successful in reducing bone loss, but human data is limited. Moreover, there is an emerging body of evidence linking the gut microbiome to cognitive, muscle and cardiometabolic function. Such studies indicate that probiotics (healthy gut bacteria) or prebiotics (food for healthy bacteria, e.g. fibre) can increase the amount of short chain fatty acids - such as butyrate -produced by the bacteria in the gut which may mediate the beneficial effects of improving gut health.
The proposed study is a double-blind, placebo-controlled randomised trial, which will investigate whether consuming a probiotic supplement containing inulin (a prebiotic soluble fibre) twice daily for 12 months will improve bone health in postmenopausal women. In addition, secondary outcomes will measure the effect of the intervention on immune system modulation and cognition as well as musculoskeletal and metabolic function as potential mediators.
One hundred and sixty postmenopausal women residing in Melbourne (Victoria, Australia) who are at least one year from their final menses will be recruited from the community via a mail out, advertisements in newspapers, social media, flyers as well as a landing page on an ACU managed website. The investigators have also applied for assisted mail outs through Services Australia for recruitment purposes. Services Australia is able to extract names and addresses of some target study demographics (females living in Melbourne aged between 40 and 65) from the Medicare database and mail them the study details on our behalf. Those wishing to participate will undergo a series of baseline assessments inclusive of bone mineral density scans, blood and stool sampling and physical activity and lifestyle questionnaires. They will then be randomised, in a blinded fashion, to consume one of the following two supplements:
Study outcomes will be measured at baseline, 6 months, and 12 months. In addition, participants will be contacted via the telephone and email at three-month and nine-month timepoints to report any adverse responses to the supplementation. At the 12-month time point, participants will cease supplementation and immediately (within 24 hours) attend a post intervention assessment and will complete identical assessment measures to those they did at baseline. Finally, at 2 weeks post supplementation cessation participants will be asked to attend an appointment to provide a final stool sample.
If it can be confirmed that long term consumption of a probiotic supplement can have beneficial effects on bone health, muscle health, and metabolic health in postmenopausal women, this intervention could be recommended in the prevention of osteoporosis and associated musculoskeletal and metabolic conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
Dietary Supplement: Pendulum WBF-038
Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.
Dietary Supplement: Pendulum Placebo
All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS). The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃.
Pendulum placebo capsules containing magnesium stearate
Total volumetric bone mineral density of the distal tibia
Percentage change in total volumetric bone density measured using high resolution peripheral quantitative computed tomography (HR-pQCT) of the distal tibia.
Time frame: 12 months
Bone mineral density of the lumbar spine
Relative change in lumbar spine (L1-L4) bone mineral density (BMD) measured using dual energy X-ray absorptiometry (DXA)
Time frame: 12 months
Bone mineral density of the hip
Relative change in total hip BMD measured using DXA
Time frame: 12 months
Tibia and radius trabecular bone volume
Relative change in tibia and radius trabecular bone volume fraction measured using HR-pQCT
Time frame: 12 months
Tibia and radius cortical area
Relative change in tibia and radius cortical area measured using HR-pQCT
Time frame: 12 months
Tibia and radius cortical volumetric bone mineral density
Relative change in tibia and radius cortical volumetric BMD measured using HR-pQCT
Time frame: 12 months
Total volumetric bone mineral density of the distal radius
Relative change in total volumetric BMD of the distal radius measured using HRpQCT
Time frame: 12 months
Serum C-terminal cross-linking telopeptide of type I collagen (ßCTX-I) - bone turnover marker
Relative change in ßCTX-I in serum
Time frame: 6 months and 12 months
Serum procollagen type 1 N-terminal propeptide (P1NP) - bone turnover marker
Relative change in P1NP levels in serum
Time frame: 6 months and 12 months
Serum osteocalcin (OC) - bone turnover marker
Relative change in OC in serum
Time frame: 6 months and 12 months
Short-chain fatty acids (SCFAs)
Relative change in SCFA levels (including butyrate) in stool
Time frame: 6 months, 12 months, and 2 weeks post intervention
16s rRNA genetic sequencing of the gut microbiota
Relative change in species-level gut microbiota composition in stool using 16s rRNA sequencing
Time frame: 6 months, 12 months, and 2 weeks post intervention
Fasting blood glucose
Relative change in fasted blood glucose levels in circulating blood
Time frame: 6 months and 12 months
Glycated haemoglobin (HbA1c)
Relative change in HbA1c levels in circulating blood
Time frame: 6 months and 12 months
Lower leg muscle area
Relative change in lower leg muscle area measured using HR-pQCT
Time frame: 12 months
Lean body mass
Relative change in appendicular lean body mass measured using DXA
Time frame: 12 months
Grip strength
Relative change in left and right hand grip strength measured using a hand dynamometer
Time frame: 6 months and 12 months
High-sensitivity C-reactive protein (hs-CRP)
Relative change in hs-CRP levels in serum
Time frame: 6 months and 12 months
Regulatory T lymphocytes (Tregs)
Relative change in circulating number of Tregs in blood
Time frame: 12 months
Oral glucose tolerance test (OGTT)
Relative change in oral glucose tolerance in circulating blood
Time frame: 6 months and 12 months
Muscle tissue glycogen content
Relative change in muscle tissue glycogen content obtained from a muscle biopsy
Time frame: 6 months and 12 months
Muscle tissue triglyceride content
Relative change in muscle tissue triglyceride content obtained from a muscle biopsy
Time frame: 6 months and 12 months
Muscle tissue type 1 fibre composition
Relative change in muscle tissue type 1 fibre proportion obtained from a muscle biopsy
Time frame: 6 months and 12 months
Lipocalin2
Relative change in Lipocalin2 (intestinal inflammation) in stool
Time frame: 6 months, 12 months, and 2 weeks post intervention
Cogstate One back Test Cognitive performance test
Relative change in speed of performance and number of errors in the One Back Test using the Cogstate cognitive assessment tool. Lower score = better performance
Time frame: 6 months and 12 months
Cogstate Groton Maze Learning Test Cognitive performance test
Relative change in number of errors in the Groton Maze Learning Test using the Cogstate cognitive assessment tool. Lower score = better performance
Time frame: 6 months and 12 months
Cogstate Continuous Paired Associate Learning Test Cognitive performance test
Relative change in accuracy of performance and number of errors in the Continuous Paired Associate Learning Test using the Cogstate cognitive assessment tool. Lower score = better performance
Time frame: 6 months and 12 months
Cogstate Social Emotional Cognition Test Cognitive performance test
Relative change in accuracy of performance in the Social Emotional Cognition Test using the Cogstate cognitive assessment tool. Higher score = better performance
Time frame: 6 months and 12 months
Depression, Anxiety and Stress Scale 21
Relative change in depression, anxiety and stress measured using the Depression Anxiety and Stress Scale 21 (DASS-21) questionnaire. The DASS-21 has a minimum score of 0 and a maximum score of 63 with higher scores indicating a worse outcome.
Time frame: 6 months and 12 months
Gastrointestinal Symptom Rating Scale
Relative change in gastrointestinal symptoms measured using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. The GSRS has a minimum score of 5 and a maximum score of 45 with higher scores indicating a worse outcome.
Time frame: 6 months and 12 months
Plasma glucagon-like peptide 1
Relative change in gut hormone glucagon-like peptide 1 \[GLP-1\] in plasma
Time frame: 6 months and 12 months
Plasma peptide tyrosine-tyrosine
Relative change in gut hormone peptide tyrosine-tyrosine \[PYY\] in plasma
Time frame: 6 months and 12 months
Plasma adiponectin
Relative change adiponectin in plasma
Time frame: 6 months and 12 months
EuroQol Five Dimensions Quality of life Medical Outcome Survey
Relative change in quality of life measured using the EuroQol Five Dimensions (EQ-5D) questionnaire. The EQ-5D has a minimum score of Level 1 and a maximum score of Level 5 with higher levels indicating a worse outcome
Time frame: 6 months and 12 months
Social Interaction Anxiety Scale
Relative change in social anxiety measured using the Social Interaction Anxiety Scale (SIAS) questionnaire. The SIAS has a minimum score of 0 and a maximum score of 80 with higher scores indicating a worse outcome.
Time frame: 6 months and 12 months
The Warwick-Edinburgh Mental Wellbeing Scale
Relative change in mental wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) questionnaire. The WEMWBS has a minimum score of 14 and a maximum score of 70 with higher scores indicating a better outcome.
Time frame: 6 months and 12 months
Continuous blood glucose level monitoring for 10 days
Relative change in blood glucose (area under the curve) over 10 days measured using a continuous glucose monitoring device
Time frame: 6 months and 12 months
Fasting blood insulin
Relative change in fasted blood insulin levels in circulating blood
Time frame: 6 months and 12 months
Fat mass
Relative change in total body fat mass measured using DXA
Time frame: 12 months
Blood metabolomics
Relative change in blood metabolites using liquid chromatography-mass spectrometry
Time frame: 12 months
Office blood pressure
Relative change in Systolic and Diastolic blood pressure measured using a sphygmomanometer
Time frame: 6 months and 12 months
The Visual Analogue Scale Pain Intensity
Relative change in current pain intensity measured using a visual analogue scale (VAS) pain intensity scale. The VAS has a minimum score of 0 and a maximum score of 10 with higher scores indicating a worse outcome.
Time frame: 6 months and 12 months
Calprotectin
Relative change in calprotectin (intestinal inflammation) in stool
Time frame: 6 months, 12 months, and 2 weeks post intervention
Muscle mass
Relative change in total body muscle mass measured using DXA
Time frame: 12 months
Plan to share: No
Ran from May 2022 to primary completion in Mar 2024, 22 months.
Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 22 months is below that.
Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.
Completion moved once since we started tracking on Sep 25, 2026: Apr 2025 → May 2025, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian Catholic University